Why U.S. Stock Futures Are Down Ahead Of Key Jobs Report For June
Pre-open movers
U.S. stock futures traded lower in early pre-market trade on Thursday ahead of the much-awaited jobs report for June.
Needham Maintains Buy on Intercept Pharmaceuticals, Lowers Price Target to $22
Needham analyst Joseph Stringer maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Buy and lowers the price target from $25 to $22.
Keybanc Maintains Overweight on Materion, Lowers Price Target to $100
Keybanc analyst Philip Gibbs maintains Materion (NYSE:MTRN) with a Overweight and lowers the price target from $106 to $100.
Keybanc Maintains Overweight on Aspen Technology, Raises Price Target to $210
Keybanc analyst Jason Celino maintains Aspen Technology (NASDAQ:AZPN) with a Overweight and raises the price target from $175 to $210.
Benchmark Initiates Coverage On NOW with Buy Rating, Announces Price Target of $13
Benchmark analyst Douglas Becker initiates coverage on NOW (NYSE:DNOW) with a Buy rating and announces Price Target of $13.
Oppenheimer Initiates Coverage On Blueprint Medicines with Outperform Rating, Announces Price Target of $80
Oppenheimer analyst Matthew Biegler initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Outperform rating and announces Price Target of $80.
Wedbush Initiates Coverage On Aprea Therapeutics with Outperform Rating, Announces Price Target of $3
Wedbush analyst Robert Driscoll initiates coverage on Aprea Therapeutics (NASDAQ:APRE) with a Outperform rating and announces Price Target of $3.
Piper Sandler Downgrades Huntington Bancshares to Neutral, Lowers Price Target to $13.5
Piper Sandler analyst Scott Siefers downgrades Huntington Bancshares (NASDAQ:HBAN) from Overweight to Neutral and lowers the price target from $14 to $13.5.
ADC Therapeutics Announced Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA in Europe and Select International Territories; ADC Therapeutics is Eligible to Receive Up to $435M, Including Milestones
ADC Therapeutics SA (NYSE: ADCT) today announced it has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (Sobi®) for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications outside of the United States, greater China, Singapore and Japan.
China Passenger Car Association Said Tesla Sold 78,906 China-made Vehicles in June
https://www.reuters.com/business/autos-transportation/tesla-sold-78906-china-made-vehicles-may-cpca-2022-07-08/#:~:text=SHANGHAI%2C%20July%208%20(Reuters),22%25%20from%20a%20year%20earlier.